













CONCISE REVIEW

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases

Pere Ginès^{1,2,3,4}  | **Laurent Castera**^{5,6,7} | **Frank Lammert**^{8,9,10} |
Isabel Graupera^{1,2,3,4} | **Miquel Serra-Burriel**¹¹ | **Alina M. Allen**¹²  |
Vincent Wai-Sun Wong¹³  | **Phillipp Hartmann**¹⁴ | **Maja Thiele**¹⁵ |
Llorenç Caballeria¹⁶ | **Robert J. de Knegt**¹⁷  | **Ivica Grgurevic**¹⁸ |
Salvador Augustin^{3,19,20} | **Emmanuel A. Tsochatzis**²¹  |
Jörn M. Schattenberg²²  | **Indra Neil Guha**²³  | **Andrea Martini**²⁴ |
Rosa M. Morillas^{3,20,25} | **Montserrat Garcia-Retortillo**²⁶ | **Harry J. de Koning**²⁷  |
Núria Fabrellas^{2,28}  | **Judit Pich**²⁹ | **Ann T. Ma**^{1,2,4}  | **M. Alba Diaz**³⁰ |
Dominique Roulot³¹ | **Philip N. Newsome**^{32,33}  | **Michael Manns**⁸ |
Patrick S. Kamath¹² | **Aleksander Krag**¹⁵  | **for the LiverScreen Consortium Investigators**

¹Liver Unit, Hospital Clinic of Barcelona, Barcelona, Spain

²August Pi I Sunyer Biomedical Research Institute, Barcelona, Spain

³Centro de Investigación En Red de Enfermedades Hepáticas Y Digestivas, Barcelona, Spain

⁴Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

⁵Department of Hepatology, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France

⁶Université de Paris, Paris, France

⁷Inserm UMR 1149, Centre de Recherche Sur L'inflammation, Paris, France

⁸Department of Medicine II, Saarland University Medical Center, Homburg, Germany

⁹Institute for Occupational Medicine and Public Health, Saarland University, Homburg, Germany

¹⁰Health Sciences, Hannover Medical School, Hannover, Germany

¹¹Epidemiology, Statistics, and Prevention Institute, University of Zurich, Zurich, Switzerland

¹²Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA

¹³Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

¹⁴Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Diego, La Jolla, California, USA

¹⁵Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital and Institute for Clinical Research, University of Southern Denmark, Odense, Denmark

¹⁶USR Metropolitana Nord, IDIAP Jordi Gol, Catalan Health Institute, Mataró, Spain

¹⁷Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, Rotterdam, the Netherlands

¹⁸Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, University of Zagreb School of Medicine and Faculty of Pharmacy and Biochemistry, Zagreb, Croatia

¹⁹Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

²⁰Universitat Autònoma de Barcelona, Barcelona, Spain

²¹UCL Institute for Liver and Digestive Health, Royal Free Hospital, University College of London, London, UK

²²Metabolic Liver Research Program, Department of Internal Medicine I, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Abbreviations: ALD, alcohol-associated liver disease; ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; CLD, chronic liver diseases; ELF, Enhanced Liver Fibrosis test; FIB-4, Fibrosis-4 Index; NAS, NAFLD score; TE, transient elastography.

This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. *Hepatology* published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

²³NIHR Nottingham Biomedical Research Center, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK

²⁴Unit of Internal Medicine and Hepatology, Department of Medicine, University-Teaching Hospital of Padova, Veneto, Italy

²⁵Liver Unit, Hospital Germans Trias i Pujol, Badalona, Spain

²⁶Liver Section, Gastroenterology Department, Department of Medicine, Hospital del Mar, Barcelona, Spain

²⁷Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands

²⁸School of Nursing, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

²⁹Clinical Trial Unit, Hospital Clínic, Barcelona, Spain

³⁰Department of Pathology, Center of Biomedical Diagnosis. Hospital Clínic, Barcelona, Spain

³¹Unité d'Hépatologie, Hôpital Avicenne, Université Paris, Bobigny, France

³²European Association for the Study of the Liver, Geneva, Switzerland

³³National Institute for Health Research Biomedical Research Center at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham, UK

Correspondence

Pere Ginès, Liver Unit, Hospital Clínic of Barcelona, Barcelona, Spain.
Email: pginès@clinic.cat

Funding information

LiverScreen Consortium and the European Commission under the H20/20 program (847989); AGAUR (2017SGR-01281); Centro de Investigación Biomedica en Enfermedades Hepáticas y Digestivas; Fundación de Investigación Sanitaria, cofunded by Instituto Carlos III—Subdirección General de Evaluación and the European Regional Development Fund (PI18/01330, PI18/00662, and PI18/00862); and Gilead's Investigator-sponsored research program (IN-ES-989-5309)

Abstract

Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate –18% to 27%–in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression.

INTRODUCTION

Cirrhosis is the eleventh most common cause of death globally, accounting for an estimated 2 million deaths per year^[1] (data taken from the Global Burden of Disease Study), indicating that cirrhosis deaths have risen from 899,000 to more than 1.32 million from 1990 to 2017.^[2] Moreover, there is marked geographical variation with Central Asia having the highest age-standardized death rate (39 deaths [36.2–41.5 95% CI] per 100,000 population), in contrast to the lowest rates seen in Australasia (5.4 [4.9–6.0 95% CI] per 100,000 population).^[2]

Approximately 75 million individuals worldwide have an alcohol-use disorder putting them at risk for

alcohol-associated liver disease (ALD). With over 2 billion adults being obese/overweight and over 400 million with diabetes, the increase in age-standardized prevalence of compensated and decompensated cirrhosis has been higher with NAFLD as compared with other etiologies of liver disease (increase of 33% for compensated cirrhosis and 55% for decompensated cirrhosis, with NAFLD, as compared to other etiologies of cirrhosis).^[2] The recognized interaction between obesity and alcohol will contribute further to a marked increase in liver disease, including HCC, which now accounts for 3.5% of all deaths worldwide.^[3] The absolute burden of viral hepatitis has also increased, although the availability of effective vaccines and treatments may reduce the burden of these diseases in the years to come.

In terms of morbidity, cirrhosis is now the seventh-leading cause of disability associated life years in people aged 50-74 years and the twelfth cause in the 25-49 age range,^[4] with annual in-hospital costs for cirrhosis in the United States alone accounting for over \$10 billion.^[5] Thus, there is an urgent need to try to identify patients with chronic liver diseases (CLD) at an earlier stage and intervene effectively before they progress to cirrhosis and decompensation and/or HCC.

This review article discusses the rationale and available evidence for screening for liver fibrosis in the population.

RATIONALE FOR SCREENING FOR LIVER FIBROSIS

To justify the application of a screening policy by health authorities, the 10 criteria of Wilson and Jungner are often still seen as guiding principles (Table 1). CLD with a long asymptomatic phase before cirrhosis develops is characterized by a relatively well-defined natural history and a high death rate, meeting the first three criteria.^[6] Most patients at risk of CLD, however, are seen in primary care, where optimal diagnostic strategies are undefined.

In population screening, the sensitivity and specificity of the test used are paramount for minimizing the risk of false-negative and false-positive cases, respectively. Conventional liver tests, such as serum aminotransferases, have poor sensitivity and specificity for identifying cirrhosis, and a liver biopsy is too invasive for a screening test. Noninvasive tests of fibrosis, such as transient elastography (TE) or serum

biomarkers, are widely available and well validated for this purpose, with good acceptability.^[7] However, longitudinal data using these tests for screening are scarce. Finally, screening using noninvasive tests may be cost-effective but requires validation.^[8]

Early diagnosis of CLD enables initiation of specific measures or treatments to prevent disease progression and improve survival, including antiviral therapy for HBV or HCV, alcohol abstinence in ALD, and behavioral changes and treatment of diabetes and obesity in NAFLD. In addition, patients with cirrhosis, once diagnosed, require surveillance for varices and HCC.

NONINVASIVE TOOLS FOR POPULATION SCREENING

A key challenge is that a test's performance varies with prevalence of the disease. This is the "spectrum effect," meaning that in low-prevalence populations the sensitivity and the positive predictive value are lower. Furthermore, any test, depending on the nature of the test and the chosen cutoff, is associated with false-positive and false-negative test results, an inherited limitation of binary decision making. A step-wise algorithm of combining noninvasive tests could reduce the rate of false-positive tests.^[9] In addition, it is important to recognize the limitation of liver biopsy as reference standard and the potential variability of all blood based biomarkers^[10] that can challenge the potential as screening tool.

Hagström et al. found only modest prognostic performance (area under the receiver operating characteristic curve from 0.54-0.71) of five indirect markers of fibrosis

TABLE 1 Summary of the 10 criteria proposed for screening for a disease in the general population^a

Factors	Criteria	Comment regarding screening for liver diseases
Disease	1. The condition sought should be an important health problem	Criterion met
	2. There should be a recognizable latent or early symptomatic stage	Criterion met
	3. The natural history of the condition, including development from latent to declared disease, should be adequately understood	Criterion met
Setting	4. Facilities for diagnosis and treatment should be available	Further research needed
Diagnosis	5. There should be a suitable test or examination	Criterion met
	6. The test should be acceptable to the population	Criterion met
	7. Case finding should be a continuing process and not a "once and for all" project	Further research needed
Treatment	8. There should be an accepted treatment for patients with recognized disease	Criterion met
	9. There should be an agreed policy on who can treat the patients	Criterion met ^b
Cost-effectiveness	10. The cost of case finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole	Further research needed

^aAdapted from Wilson and Jungner for the World Health Organization.

^bDoes not apply to alcohol-associated liver disease, NAFLD, or viral hepatitis in low-income countries.

(aspartate aminotransferase [AST]-to-platelet ratio index [APRI], Fibrosis-4 Index [FIB-4], BARD, Forns, and NAFLD score [NAS]) to predict future development of cirrhosis and severe liver disease in the general population.^[11] More successful approaches involve TE, which has been applied as screening tool in more than 6,000 people from population studies from France, China, Spain, and the UK.^[12-15] TE was in general acceptable, and after availability of the XL probe, which was designed to obtain accurate values for obese subjects, reliable results were obtained in over 97% of participants. However, the true diagnostic accuracy with liver biopsy as gold standard is less investigated in the screening setting. In a subgroup analysis of a biopsy-controlled study, TE had a sensitivity of 86% and specificity of 97% in a population in which 6% had advanced fibrosis.^[15] Some of the tools that could be used in population screening are given in Table 2. Enhanced Liver Fibrosis test (ELF) has also been proposed, but studies with information about its potential as screening tool of fibrosis are limited.^[16,17]

PREVALENCE OF LIVER FIBROSIS IN GENERAL POPULATION IN DIFFERENT PARTS OF THE WORLD

Europe

A limited number of studies have reported results on liver fibrosis screening using different noninvasive methods and cutoffs (Table 3).^[11,12,14,18-24] Liver fibrosis detection rates ranged between 0.7% and 7.5% in population-based cohorts versus 18%-27% in cohorts at risk for CLD.^[25] Prevalence of cirrhosis reported in half of the studies ranged from 0.25% to 0.76%. NAFLD was the main cause of liver fibrosis in all studies.

North America

Between 1988 and 2016, NAFLD prevalence increased from 20.0% to 31.9%, whereas that of chronic hepatitis C decreased nearly 2-fold (1.6%–0.9%), and chronic hepatitis B and ALD remained stable (0.3%–0.4% and 0.8%–1.0%, respectively).^[26]

In NAFLD, prevalence estimates of advanced fibrosis have ranged between 3.2% and 10.3%, depending on the assessment method and population.^[27,28]

Asia

Despite the success of universal infant vaccination and antiviral therapy, chronic hepatitis B affects 0.6%–9.8% of the general population and remains a leading cause of cirrhosis and HCC. NAFLD now affects 29.6% of the general population.^[29] Alcohol consumption is also on the rise.

TABLE 2 Advantages and limitations of noninvasive tests of fibrosis used in population screening

	Evidence to support		Practical issues			
	Accuracy in low prevalent populations	Tested in screening setting	Cost-effectiveness in screening	Price	Requires operator training	Point-of-care assessment
Transient elastography	++	++	++	+++	++	+++
Direct fibrosis markers (e.g., ELF)	+	+	+	++	+	I
Indirect markers (e.g., FIB-4)	+	+	+	+	+	I
Sequential testing (e.g., FIB-4 and ELF)	+	+	+	++	+	I

Note: The table rates the current evidence base to support different screening tools and the level of practical barriers for implementation. The rating is arbitrary and combines strength and amount of data: -, none or no data; +, limited data; ++, moderate data; +++, significant data.

TABLE 3 Prevalence of liver fibrosis and cirrhosis in general population-based studies in Europe

Reference	Country	Sample size	Setting	Noninvasive fibrosis test	Definition of fibrosis	Prevalence of fibrosis ≥ 2	Definition of cirrhosis	Prevalence of cirrhosis
Poynard 2010 ^[15]	France	7463	Consecutive subjects > 40 years old attending health examination centers	FibroTest	FibroTest ≥ 0.48	0.7%–2.8%	FibroTest ≥ 0.48 , LSM ≥ 7.1 kPa, and clinical signs or liver biopsy	0.1%–0.3%
Roulot 2011 ^[10]	France	1358 (1190 with valid results)	Consecutive subjects > 45 years old attending a medical check-up	TE	LSM ≥ 7.1 kPa	7.5%	LSM ≥ 13 kPa and liver biopsy	0.76%
Zelber-Sagi 2012 ^[16]	Israel	375 (338 with valid results)	National Health Survey	FibroTest	FibroTest ≥ 0.22 ; FibroTest ≥ 0.32 ; FibroTest ≥ 0.59	25.7%; 12.8%; 0.9%	FibroTest ≥ 0.75	0.3%
Koehler 2016 ^[17]	Netherlands	3439 (3180 with valid results)	Population-based, randomly selected	TE	LSM ≥ 8 kPa	5.6%	LSM ≥ 13 kPa	0.6%
Fabrellas 2018 ^[18]	Spain	295 (292 with valid results)	Population-based randomly selected (2/3 with metabolic factors)	TE	LSM ≥ 8 kPa	4%	—	—
Petta 2018 ^[19]	Italy	890	Population-based study	TE	LSM ≥ 9.6 kPa	4%	—	—
Caballeria 2018 ^[12]	Spain	3076 (3014 with valid results)	Population-based, randomly selected 18–75-year-olds	TE	LSM ≥ 9.0 kPa	3.6%	—	—
Abeysekera 2020 ^[20]	UK	4021 (3600 with valid results, mean age 24 years)	Avon Longitudinal Study of Parents and Children	TE	LSM ≥ 7.9 kPa	2.4%	LSM ≥ 11.7 kPa	0.25%
Hagström, 2020 ^[9]	Sweden	126,941	Cohort of health check-ups and outpatients from primary care setting	FIB-4, BARD, APRI, Forns, NAS	FIB-4 > 2.67; BARD > 3; APRI > 1.5; Forns > 6.9; NAS > 0.676	0.3%–1.4%	—	—

Abbreviation: LSM, liver stiffness measurement.

Few studies have determined the prevalence of liver fibrosis, both in general population and at-risk populations (Table S1). Studies from Hong Kong reported increased TE values suggestive of advanced fibrosis in 2% and 17.7% of these two populations, respectively.^[13,30]

Other parts of the world

A Markov simulation based on obesity data in Australia projects a 25% increase in NAFLD by 2030, with 85% increase in cirrhosis and NAFLD-related liver deaths.^[31] Most cirrhosis deaths in Latin America are due to alcohol, except for tropical Latin America, where the major cause of cirrhosis is hepatitis C. No data on population screening for liver fibrosis are available from Latin America or Africa. In Africa, the major causes of death due to cirrhosis are hepatitis B and hepatitis C.^[2]

POTENTIAL STRATEGIES FOR SCREENING AND LIMITATIONS

A major reason for the low proportion of patients with early diagnosis of advanced fibrosis and/or cirrhosis is the lack of referral pathways, even if elevated liver enzymes are identified in primary care. In addition, the care pathways for ALD or NAFLD are not always well structured. In general, strategies for early diagnosis of CLD, advanced fibrosis, and/or cirrhosis can be designed as population-based or targeted screening. A population-based, cross-sectional study with 3076 participants in the Barcelona area using TE for “at front” screening in primary care reported that TE values < 9.2 kPa had highest accuracy to exclude fibrosis stages F2–F4.^[14] A more targeted approach focusing on patients with risk factors, such as harmful alcohol consumption or type 2 diabetes, may result in a higher rates of cirrhosis detected than a global approach.^[25] The Nottingham liver disease stratification pathway for the identification of advanced CLD^[32] used (i) raised AST-to-alanine aminotransferase (ALT) ratio ≥ 0.8 , (ii) harmful alcohol use, or (iii) fatty liver index ≥ 60 as criteria for referral from primary to secondary care. Among patients fulfilling these criteria, 23% of 968 patients had TE values ≥ 8 kPa, of whom 39% would have gone undetected. Markov modeling estimated the pathway to be cost-effective.^[33] Similar one-step pathways, but based on APRI score in primary care with subsequent TE, are being evaluated in the population-based screening program for asymptomatic cirrhosis (SEAL) in Germany (<https://www.lebervorsorge.de/seal/>). To assess two-step screening algorithms, a primary care referral pathway combining FIB-4 and ELF for patients with NAFLD was evaluated in a longitudinal study in London.^[18] Five times more cases of advanced fibrosis

and cirrhosis were detected, and unnecessary referrals from primary to secondary care decreased by almost 90% using this strategy.

The implementation of a screening program has to take into account not only region-specific health risk profiles (age, sex, comorbidities, ethnicity) but region-specific participation barriers and health inequities (socio-economic differences, distance, mobility), the structure of the health care system (in particular community and primary care, links to other screening programs such as colon and breast cancer), as well as regulatory requirements (ethics, data protection, coverage of costs).

A general strategic framework for early diagnosis of CLD based on current knowledge is proposed in Figure 1.

COST-EFFECTIVENESS OF LIVER FIBROSIS SCREENING

In recent years, evidence regarding the cost-effectiveness of liver fibrosis screening has been mounting. Using noninvasive procedures for risk stratification, and compared with the current standard-of-care pathways, various economic models show highly cost-effective results. These results are consistent across a wide range of target populations and health care systems, mostly in European settings.^[8,33–37] Estimates range between \$6,000 per quality-adjusted life-year (QALY) in low-prevalence general population settings to \$2,000 per QALY in at-risk populations, such as heavy alcohol consumers or patients with metabolic syndrome. These numbers are well below the thresholds that allow new therapies to enter the portfolio of covered services in most developed countries (\$100,000 in the United States and between \$25,000 and \$50,000 in Europe). Their importance lies in their opportunity cost. Provided that less cost-effective therapies are being administered, using the same budget but shifting it toward liver fibrosis screening would yield a better societal return.

SCREENING IN PEDIATRIC POPULATIONS

Approximately 9.6% of children and adolescents have fatty liver, and 1%–2% of the general pediatric population have at least some histopathological evidence of portal and/or perisinusoidal fibrosis associated with fatty liver based on autopsy studies,^[38] which is lower than the liver fibrosis prevalence in adults. In light of this low prevalence in children, universal screening for liver fibrosis in that population cannot be recommended at this time, but screening should be guided by risk factors, such as personal and family history of liver disease or presence of obesity.

Screening for liver fibrosis with serum ALT levels is insufficient in children, as fibrosis can be detected on




FIGURE 1 Proposal of a general strategic framework for screening of liver fibrosis in primary care. Current evidence suggests that the target population for screening should have risk factors for chronic liver diseases (CLD), including high-risk alcohol consumption and/or components of the metabolic syndrome. The prevalence of liver fibrosis is very low in subjects without these risk factors (Risk Stratification I). The first additional step needed is based on a serum surrogate marker of fibrosis with high negative predictive value to rule out subjects with very low likelihood of fibrosis (Risk Stratification II). Some screening studies suggest that Fibrosis-4 Index (FIB-4) could be used as marker to rule out fibrosis, but further studies are necessary.^[7,25] A single large study suggests that fatty liver index (FLI) could also be useful, but more information is clearly needed.^[14] The second step avails of a noninvasive marker of fibrosis to rule in subjects with high likelihood of significant fibrosis who then should be referred to secondary care or a liver center for further evaluation (screening test in high-risk individuals). Tools/tests to be used in this second step include transient elastography (TE), but this strategy may be expensive and not usually available in primary care settings.^[7,8,25] Enhanced Liver Fibrosis (ELF) has been shown to be accurate in cohorts with high prevalence of fibrosis, but studies are needed in screening populations that have low prevalence of fibrosis.^[16,25] *Tests that may be used to rule out hepatic fibrosis include FIB-4 and FLI. **Tests that may be used to rule in hepatic fibrosis include TE and ELF

liver biopsy in 12% of children with suspected NAFLD and normal ALT levels.^[39] The gold standard in the assessment of pediatric liver fibrosis is still liver biopsy,^[39] but it might soon be replaced by noninvasive serum and imaging screening modalities, which are getting better at diagnosing (early) liver fibrosis in children (Table S2).^[40,41]

CONCLUSIONS AND FUTURE DIRECTIONS

There is an urgent need to change the paradigm of diagnosis of CLD from late diagnosis (i.e., decompensated cirrhosis) to early diagnosis (i.e., fibrosis or compensated cirrhosis). This new approach would require

TABLE 4 Examples of projects evaluating screening for liver fibrosis in the population in different areas of the world

Name	Geographical area	Area and/or number of subjects	Characteristics
Renown	Nevada (United States)	30,000	Subjects with risk factors for NAFLD
Scarred Liver Project	Nottingham (UK)	GP practices in a population of 700,000	Subjects with risk factors for CLD
LiverScreen	Seven countries in Europe	30,000	Population-based
SEAL	Germany (two federal states: Rheinland-Pfalz + Saarland)	12,000 plus 22,500 controls	Detection of asymptomatic cirrhosis in primary care

Abbreviation: GP, general practice.

identification of asymptomatic patients using noninvasive methods of assessment of fibrosis in large portions of the population. A main lesson learned from cancer screening is that selection of individuals with a high pre-test probability leads to higher economic efficiency. Early research points toward 3-fold improvements in efficiency when at-risk populations are targeted.^[8] However, there is need for studies with large sample sizes addressing the most important gaps of knowledge, particularly comparing existing noninvasive tests of fibrosis in terms of accuracy and applicability in specific settings, evaluating cost-effectiveness of screening, and investigating potential beneficial effects in the long term.

There are several initiatives worldwide evaluating the implementation of different methods of screening for liver fibrosis in the population (Table 4). When implemented, screening will likely have a remarkable impact on the practice of hepatology. Most patients with CLD may subsequently be detected in early stages, thus potentially decreasing the incidence of hepatic decompensation and HCC and the need for some specialized therapies, such as liver transplantation.

CONFLICT OF INTEREST


Dr. Gines advises and received grants from Gilead, Grifols, and Mallinckrodt. He advises Novartis, Martin, and Ferring. Dr. Castera consults and is on the speakers' bureau for Echosens, Gilead, Intercept, and Novo Nordisk. He consults Alexion, MSD, and Pfizer. Dr. Wong consults for Gilead, 3V-Bio, AbbVie, Allergan, Boehringer Ingelheim, Echosens, Inventiva, Merck, Novartis, Novo Nordisk, Pfizer, Prosciento, Sagimet, TARGET, and Terns. Dr. de Knecht advises, is on the speakers' bureau, and received grants from Gilead. He advises and is on the speakers' bureau for AbbVie. He advises Bristol-Myers Squibb and Merck. He is on the speakers' bureau for Echosens and Philips. Dr. Thiele advises GE and is on the speakers' bureau for Echosens, Norgine, and Siemens. Dr. Grgurevic is on the speakers' bureau for Echosens. Dr. Augustin consults, is on the speakers' bureau, and received grants from Gilead. He consults and is on the speakers' bureau for Novartis. He consults and is employed by Boehringer Ingelheim. He consults for Intercept, Pfizer, Ferrer, and IQVIA. He is on

the speakers' bureau for Allergan, MSD, and Menarini. Dr. Tsochatzis consults for Gilead, Intercept, Pfizer, and Orphalan. Dr. Schattenberg consults and received grants from Gilead, Boehringer Ingelheim, and Siemens. He consults for Bristol-Myers Squibb, Echosens, Genfit, Intercept, Madrigal, Nordic, Novartis, Pfizer, Roche, and Sanofi. He is on the speakers' bureau for Falk Foundation. Dr. Guha received grants from Gilead. Dr. Krag advises, is on the speakers' bureau, and received grants from Norgine and Siemens. He is on the speakers' bureau for Nordic.

ORCID

Pere Ginès  <https://orcid.org/0000-0003-4657-4504>

Alina M. Allen  <https://orcid.org/0000-0002-8393-8410>

Vincent Wai-Sun Wong  <https://orcid.org/0000-0003-2215-9410>

Robert J. de Knecht  <https://orcid.org/0000-0003-0934-6975>

Emmanuel A. Tsochatzis  <https://orcid.org/0000-0001-5069-2461>

Jörn M. Schattenberg  <https://orcid.org/0000-0002-4224-4703>

Indra Neil Guha  <https://orcid.org/0000-0002-6940-5861>

Harry J. de Koning  <https://orcid.org/0000-0003-4682-3646>

Núria Fabrellas  <https://orcid.org/0000-0001-6720-0291>

Ann T. Ma  <https://orcid.org/0000-0002-9059-111X>

Philip N. Newsome  <https://orcid.org/0000-0001-6085-3652>


Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>


Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>


Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

Aleksander Krag  <https://orcid.org/0000-0002-9598-4932>

REFERENCES

- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol.* 2019;70:151–71.
- Sepanlou SG, Safiri A, Bisignano C, Ikuta K, Merat S, Saberifirooz M, Poustchi H, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 2020;5:245–66.

3. National Cancer Institute. Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. Bethesda, Maryland: National Cancer Institute. [Cited 2020 July]. Available from: <https://seer.cancer.gov/statfacts/html/livibd.html>.
4. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396:1204–22.
5. Allen AM, Kim WR, Moriarty JP, Shah ND, Larson JL, Kamath PS. Time trends in the health care burden and mortality of acute on chronic liver failure in the United States. *Hepatology*. 2016;64:2165–72.
6. Schuppan D, Afdhal NH. Liver cirrhosis. *Lancet*. 2008;371:838–51.
7. EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. 2015;63:237–64.
8. Serra-Burriel M, Graupera I, Torán P, Thiele M, Roulot D, Wai-Sun Wong V, et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. *J Hepatol*. 2019;71:1141–51.
9. Majumdar A, Campos S, Gurusamy K, Pinzani M, Tsochatzis ET. Defining the minimum acceptable diagnostic accuracy of non-invasive fibrosis testing in cirrhosis: a decision analytic modeling study. *J Hepatol*. 2020;71:627–42.
10. Karsdal MA, Krarup H, Sand JMB, Christensen PB, Gerstoft J, Leeming DJ, et al. Review article; the efficacy of biomarkers in chronic fibroproliferative diseases—early diagnosis and prognosis with liver fibrosis as an exemplar. *Aliment Pharmacol Ther*. 2014;40:233–49.
11. Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar M. Ability of non-invasive scoring systems to identify individuals in the population at risk for severe liver disease. *Gastroenterology*. 2020;158:200–14.
12. Roulot D, Costes J-L, Buyck J-F, Warzocha U, Gambier N, Czernichow S, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. *Gut*. 2011;60:977–84.
13. Wong V-S, Chu W-W, Wong G-H, Chan R-M, Chim A-L, Ong A, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. *Gut*. 2012;61:409–15.
14. Caballería L, Pera G, Arteaga I, Rodríguez L, Alumà A, Morillas RM, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. *Clin Gastroenterol Hepatol*. 2018;16:1138–45.
15. Harman DJ, Ryder SD, James MW, Wilkes EA, Card TR, Aithal GP, et al. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: a cross-sectional study using transient elastography. *Aliment Pharmacol Ther*. 2018;47:504–15.
16. Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the Enhanced Liver Fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. *Gastroenterology*. 2018;154:1369–79.
17. Vali Y, Lee J, Boursier J, Spijker R, Löffler J, Verheij J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. *J Hepatol*. 2020;73:252–62.
18. Srivastava A, Gailer R, Tanwar S, Trembling P, Parkes J, Rodger A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. *J Hepatol*. 2019;71:371–78.
19. Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMC Gastroenterol*. 2010;10:40.
20. Zelber-Sagi S, Ratziu V, Zvibel I, Goldiner I, Blendis L, Morali G, et al. The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population. *Eur J Gastroenterol Hepatol*. 2012;24:262–9.
21. Koehler EM, Plompen EPC, Schouten JNL, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. *Hepatology*. 2016;63:138–47.
22. Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, et al. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. *Plos One*. 2018;13:e0200656.
23. Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxi A, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. *Liver Int*. 2018;38:2060–8.
24. Abeysekera KWM, Fernandes GS, Hammerton G, Portal AJ, Gordon FH, Heron J, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study. *Lancet Gastroenterol Hepatol*. 2020;5:295–305.
25. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. *Lancet Gastroenterol Hepatol*. 2017;2:288–97.
26. Younossi ZM, Stepanova M, Younossi Y, Golabi P, Mishra A, Rafiq N, et al. Epidemiology of chronic liver diseases in the USA in the past three decades. *Gut*. 2020;69:564–8.
27. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology*. 2013;57:1357–65.
28. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*. 2016;64:73–84.
29. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2019;4:389–98.
30. Kwok R, Choi KC, Wong G-H, Zhang Y, Chan H-Y, Luk A-Y, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. *Gut*. 2016;65:1359–68.
31. Adams LA, Roberts SK, Strasser SI, Mahady SE, Powell E, Estes C, et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. *J Gastroenterol Hepatol*. 2020;35:1628–35.
32. Chalmers J, Wilkes E, Harris R, Kent L, Kinra S, Aithal G, et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. *Frontline Gastroenterol*. 2020;11:86–92.
33. Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. *BMJ Open*. 2017;7:e015659.
34. Asphaug L, Thiele M, Krag A, Melberg HO. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. *Hepatology*. 2020;71:2093–104.
35. Tapper EB, Hunink MGM, Afdhal NH, Lai M, Sengupta N. Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score. *PLoS One*. 2016;11:e0147237.
36. Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisanthanarak P, Charoensak A, Washirasaksiri C, et al. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. *Medicine (Baltimore)*. 2017;96:e6585.

37. Congly SE, Shaheen AA, Swain MG. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting. *PLoS One*. 2021;16:e0251741.
38. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics*. 2006;118:1388–93.
39. Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, et al. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. *J Pediatr*. 2014;164:707–13.
40. Alkhoury N, Mansoor S, Giammaria P, Liccardo D, Lopez R, Nobili V, et al. The development of the pediatric NAFLD fibrosis score (PNFS) to predict the presence of advanced fibrosis in children with nonalcoholic fatty liver disease. *PLoS One*. 2014;9:e104558.
41. Kim JR, Suh CH, Yoon HM, Lee JS, Cho YA, Jung AY, et al. The diagnostic performance of shear-wave elastography for liver fibrosis in children and adolescents:

a systematic review and diagnostic meta-analysis. *Eur Radiol*. 2018;28:1175–86.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website. Supplementary Material

How to cite this article: Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, et al; for the LiverScreen Consortium Investigators. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. *Hepatology*. 2022;75:219–228. doi: [10.1002/hep.32163](https://doi.org/10.1002/hep.32163)